Over the past 5 years, the FDA has approved an average of 51 novel drugs annually. As a manufacturer prepares to bring any new drug to market, there are several important decisions to be made along the way. Among these is the distribution network. 

With all of the resources that go into developing a drug on the front end (R&D, clinical trials, etc.), distribution can at times be pushed to the back burner. However, the distribution network for a drug should not – and cannot- be left as an afterthought until it is time to hit the market. In fact, there are various benefits that come with identifying the right network and partner(s) early on in the commercialization process…